Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A small study looked at response rates among those with HRAS-mutant head and neck carcinoma.
Zenocutuzumab targets tumors with a specific genetic alteration, making it potentially active against cancer at multiple locations.
A novel drug that blocks multiple cancer-causing mutations shows promise, especially for combination therapy.
A study in mice suggests that therapies approved for breast cancer may also combat other types, including colorectal and stomach cancer.
MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.